Filing Flows › Comparisons › MXCT vs OABI
Maxcyte vs OmniAb: MXCT and OABI compared
Maxcyte is the larger company: $7.3M of revenue in its latest quarter (Q2 2026) against $4.0M for OmniAb (Q3 2026). OmniAb is growing faster (+78% against -14% a year earlier). Maxcyte is more profitable, with an operating margin of -140.7% against -409.9%.
Where the money goes: MXCT and OABI
Maxcyte (MXCT) · Q2 2026
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
OmniAb (OABI) · Q3 2026
OmniAb, Q3 2026: revenue $4.0M (+78% year over year), operating margin -409.9%, net loss $15.7M, operating cash flow $10.6M. The chart follows the revenue to costs, profit and cash.
| Maxcyte (MXCT) | OmniAb (OABI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $7.3M | $4.0M |
| Revenue growth, Y/Y | -14% | +78% |
| Operating margin | -140.7% | -409.9% |
| Net earnings | −$8.9M | −$15.7M |
| Net margin | -122.0% | -393.9% |
| Operating cash flow | −$4.7M | $10.6M |
Where the revenue comes from
Maxcyte
- Product sales: $4.1M (56%)
- Licenses: $2.6M (36%)
- Assay and other service revenue: $583K (8%)
OmniAb
- Service revenue: $2.8M (71%)
- xPloration revenue: $703K (18%)
- Royalty revenue: $355K (9%)
- License and milestone revenue: $100K (3%)
Questions
Which is bigger, Maxcyte or OmniAb?
Maxcyte is the larger company: $7.3M of revenue in its latest quarter (Q2 2026) against $4.0M for OmniAb (Q3 2026).
Is Maxcyte or OmniAb growing faster?
OmniAb is growing faster (+78% against -14% a year earlier).
Which is more profitable, Maxcyte or OmniAb?
Maxcyte is more profitable, with an operating margin of -140.7% against -409.9%.
More: Maxcyte earnings · how Maxcyte makes money · OmniAb earnings · how OmniAb makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.